Tag - CytoAgents

Virtual Venture & IP Conference panel highlights life science ventures and COVID

How are life science ventures leveraging their technologies to help mitigate the spread and virulence of the novel coronavirus? The Invent Penn State Venture & IP Conference panel “Life Science Ventures Addressing COVID-19” will explore this topic from 4:25-5:20 p.m. on Thursday, April 15. Registration for the all-virtual Invent Penn State Venture & IP Conference, happening April 15-16, is currently open to the public. Panel members include: Teresa Whalen – CEO, CytoAgents Inc.: As a biotech innovator, health care […]

CytoAgents looks forward to a big 2021 and beyond

Up next are two clinical trials, a phase-two clinical trial for GP1681 in the area of Covid-19 and a separate clinical that will determine how it works with CAR-T patients. It’s shaping up to be a busy year for Pittsburgh-based CytoAgents, an early stage pharmaceutical company based in Pittsburgh whose drug candidate. Read more >>

Meet AlphaLab Health’s inaugural class of companies

Innovation Works and Allegheny Health Network today announced seven companies selected for the inaugural class of AlphaLab Health, a newly created business accelerator the two organizations launched this year to provide promising health-care and life-sciences businesses with the resources and support they need to grow and thrive. CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system […]

CytoAgents Receives Second Round of NIH Funding to Accelerate Treatment for Cytokine Storm

CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2 million National Institutes of Health (NIH) grant, the second NIH grant in a year. Read more >>

Wolf Administration Highlights Development of Promising New Drug Candidate to Treat COVID-19

On Wednesday, Department of Community and Economic Development (DCED) Deputy Secretary Steve D’Ettorre and Ben Franklin Technology Partners Innovation Works Chief Executive Officer Richard Lunak joined Teresa Whalen, CEO of Pittsburgh-based CytoAgents, to highlight the development of a new COVID-19 treatment. “This exciting new development was made possible by the strong partnerships the Wolf Administration has fostered with our Ben Franklin Technology Partners and the companies they support, like CytoAgents,” said D’Ettorre. Read more >>

Teresa Whalen talks about CytoAgents and the treatment of Cytokine Storm

Teresa Whalen is the CEO of CytoAgents, a startup focused on the development of solutions to combat persistent and potentially deadly strains of Influenza, COVID19, and other viruses. Teresa’s career spans 20 years in the healthcare industry, including health technology executive, life sciences investor, and clinical pharmacist. She has brought multiple successful life-changing healthcare products to market. Read more >>